X4 Pharmaceuticals (XFOR) Interest Coverage Ratio (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Interest Coverage Ratio of 10.83 for Q4 2025, up 11.17% on a QoQ basis from 12.19 in Q3 2025, and up 30.16% year-over-year from 8.32 in Q4 2024.
X4 Pharmaceuticals (XFOR) Interest Coverage Ratio (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Interest Coverage Ratio history runs 9 years deep, the most recent figure standing at 10.83 for Q4 2025.
- Quarterly Interest Coverage Ratio rose 30.16% year-over-year to 10.83 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 9.79 (down 135.7% YoY) and the FY2025 annual result came in at 0.41, down 106.06% from the prior year.
- Interest Coverage Ratio was 10.83 for Q4 2025 at X4 Pharmaceuticals, up from 12.19 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 32.68 in Q2 2024 and bottomed at 162.91 in Q4 2022.
- A 5-year average of 21.9 and a median of 18.23 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio sank 1189.04% — and 2024, when it jumped 245.37%.
- X4 Pharmaceuticals' Interest Coverage Ratio stood at 12.64 in 2021, then plunged by 1189.04% to 162.91 in 2022, then jumped by 91.8% to 13.36 in 2023, then declined by 16.02% to 15.5 in 2024, then soared by 30.16% to 10.83 in 2025.
- Business Quant data shows XFOR's Interest Coverage Ratio at 10.83 in Q4 2025, 12.19 in Q3 2025, and 11.75 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -0.38 |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -10.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.83 |
| Sep 30, 2025 | -12.19 |
| Jun 30, 2025 | -11.75 |
| Mar 31, 2025 | -4.29 |
| Dec 31, 2024 | -15.50 |
| Sep 30, 2024 | -14.29 |
| Jun 30, 2024 | 32.68 |
| Mar 31, 2024 | -19.90 |
| Dec 31, 2023 | -13.36 |
| Sep 30, 2023 | -16.65 |
| Jun 30, 2023 | -22.48 |
| Mar 31, 2023 | -26.42 |
| Dec 31, 2022 | -162.91 |
| Sep 30, 2022 | -19.80 |
| Jun 30, 2022 | -22.41 |
| Mar 31, 2022 | -23.29 |
| Dec 31, 2021 | -12.64 |
| Sep 30, 2021 | -20.78 |
| Jun 30, 2021 | -20.99 |
| Mar 31, 2021 | -20.13 |